Skip to main content

Table 2 Results of base case cost-effectiveness analysis

From: Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran

Strategy Cost($) Incr Cost($)a Effb Incr Effc ICER($) Special
No screening 1455.07 0 7.40 0 0 Base line
SARC-F 1809.41 354.34 7.59 0.19 1897.84  
SARSA-Mod 3140.83 1685.76 8.30 0.90 1881.96  
MSRA 3151.27 1696.20 8.30 0.89 1898.33  
EWGSOP 3518.75 2063.68 8.50 1.10 1875.67  
  1. aIncremental costs, bEffectiveness, cIncremental Effectiveness